According to the Zhitong Finance App, Dacheng Biochemical Technology (00809) announced its 2026 interim results, with revenue of approximately HK$1.04 billion, a year-on-year decrease of 15.36%; net loss of approximately HK$207 million, up 33.69% year on year; and loss of HK$0.12 per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.